RARS2 Activators

RARS2 Activators comprise a diverse range of compounds that indirectly enhance the functional activity of RARS2, a mitochondrial aminoacyl-tRNA synthetase essential for mitochondrial protein synthesis. Compounds like Resveratrol, Metformin, Pioglitazone, Bezafibrate, and Berberine play a significant role in enhancing mitochondrial biogenesis and function. Resveratrol, known for its effects on sirtuin pathways, can upregulate mitochondrial biogenesis, potentially increasing the demand for RARS2 activity in mitochondrial tRNA aminoacylation. Similarly, Metformin and Pioglitazone, through AMPK and PPAR-γ activation respectively, promote mitochondrial biogenesis, which could lead to an increased requirement for RARS2's role in tRNA charging. Bezafibrate, by activating PPAR pathways, enhances mitochondrial content and functionality, potentially augmenting the need for RARS2-mediated processes. Berberine, through its AMPK-activating properties, also contributes to enhanced mitochondrial function, which may upregulate RARS2 activity.

Additionally, compounds like Leucine, EPA, Rapamycin, AICAR, SRT1720, Urolithin A, and NAD+ further contribute to the indirect activation of RARS2 by modulating mitochondrial dynamics and function. Leucine, an essential amino acid, stimulates mTOR signaling, potentially enhancing protein synthesis and indirectly increasing RARS2 activity. Rapamycin, although an mTOR inhibitor, can paradoxically enhance mitochondrial biogenesis in certain contexts, potentially increasing the demand for RARS2's function. AICAR and SRT1720, by activating AMPK and SIRT1 respectively, promote mitochondrial biogenesis and function, indirectly enhancing RARS2's role in mitochondrial tRNA aminoacylation. Urolithin A, as a mitophagy inducer, leads to healthier mitochondria